Although pneumothorax has been reported to be a major pulmonary adverse event in 
patients treated with pazopanib, a multikinase inhibitor, drug-induced 
interstitial lung disease (DILD) has not been reported. A 74-year-old Japanese 
man who received pazopanib for the treatment of femoral leiomyosarcoma and lung 
metastasis presented with dyspnea and fatigue. He had mild interstitial 
pneumonia when pazopanib treatment was initiated. Chest computed tomography 
revealed progressive bilateral ground-glass opacity (GGO) and traction 
bronchiectasis. We diagnosed DILD due to pazopanib. The patient's pazopanib 
treatment was interrupted and a steroid was administered. The symptoms and GGO 
were improved with treatment. Physicians should be aware of DILD due to 
pazopanib in patients with pre-existing interstitial lung disease.